natgillin/translations-raw huggingface dataset:
If you are taking cyclosporin (medicine to suppress your immune system) during therapy with Epoetin alfa HEXAL, your doctor may order special blood tests to measure cyclosporin levels.
Če med zdravljenjem z zdravilom Epoetin alfa HEXAL jemljete ciklosporin (zdravilo za zaviranje imunskega sistema), lahko zdravnik naroči dodatne preiskave krvi, s katerimi bo izmeril vrednosti ciklosporina.
There is not much experience with Epoetin alfa HEXAL in pregnant women or women who are breast-feeding.
Izkušenj z zdravljenjem nosečnic in doječih mater z zdravilom Epoetin alfa HEXAL ni veliko.
Important information about some of the ingredients of Epoetin alfa HEXAL
Pomembne informacije o nekaterih sestavinah zdravila Epoetin alfa HEXAL
HOW TO USE EPOETIN ALFA HEXAL
KAKO UPORABLJATI ZDRAVILO EPOETIN ALFA HEXAL
Your doctor will conduct investigations, for example blood tests, to decide if it is necessary for you to have Epoetin alfa HEXAL.
Zdravnik bo opravil preiskave, na primer krvne preiskave, da se bo odločil, ali vas je treba zdraviti z zdravilom Epoetin alfa HEXAL.
He/ she will work out the correct dose of Epoetin alfa HEXAL for you to use and how long the treatment should continue.
Nato bo določil ustrezni odmerek zdravila Epoetin alfa HEXAL, ki ga boste uporabljali, ter kako dolgo naj bi zdravljenje potekalo.
The Epoetin alfa HEXAL pre-filled syringe is ready for use.
Z zdravilom Epoetin alfa HEXAL napolnjena injekcijska brizga je pripravljena za uporabo.
Epoetin alfa HEXAL should not be shaken.
Zdravilo Epoetin alfa HEXAL je sterilno, ne vsebuje konzervansov in je namenjeno zgolj enkratni uporabi.
201 Kidney patients
201 Zdravila Epoetin alfa HEXAL ne pretresajte.
Epoetin alfa HEXAL is given by injection into a vein (intravenously).
Zdravilo Epoetin alfa HEXAL se injicira v veno (intravensko).
Cancer patients or patients scheduled for major orthopaedic surgery
Bolniki z rakom in bolniki, naročeni na večji ortopedski kirurški poseg
Epoetin alfa HEXAL is given by injection under the skin (subcutaneously).
Zdravilo Epoetin alfa HEXAL se injicira pod kožo (subkutano).
When your condition has been brought under control, you will receive regular doses of Epoetin alfa HEXAL.
Ko bo stanje nadzorovano, boste dobivali redne odmerke zdravila Epoetin alfa HEXAL.
When your condition has been brought under control, you will receive regular doses of Epoetin alfa HEXAL between 25 and 50 IU/ kg twice a week in two equal injections.
Ko bo stanje nadzorovano, boste dobivali redne odmerke zdravila Epoetin alfa HEXAL, velike med 25 in 50 i. e. / kg, dvakrat na teden, v dveh enakih odmerkih.
After your condition has been brought under control, you will receive regular doses of Epoetin alfa HEXAL between 17 and 33 IU/ kg, three times a week.
Ko bo nadzor dosežen, boste dobivali redne odmerke zdravila Epoetin alfa HEXAL, med 17 in 33 i. e. na kilogram, trikrat na teden.
Alternatively, Epoetin alfa HEXAL can be administered as an initial dose of 450 IU/ kg once a week by injection under the skin.
Zdravilo Epoetin alfa HEXAL je mogoče dajati tudi enkrat na teden, pri čemer je začetni odmerek 450 i. e. / kg, ki se injicira pod kožo.
Your doctor will check that your haemoglobin does not exceed a certain level.
Zdravnik bo preveril, da hemoglobin ne preseže neke
202 Use in adult patients in an autologous predonation programme
Zdravljenje z zdravilom Epoetin alfa HEXAL je treba nadaljevati še en mesec po končanem zdravljenju s kemoterapijo.
You will receive Epoetin alfa HEXAL during the 3 weeks before your surgery.
Zdravilo Epoetin alfa HEXAL boste prejemali 3 tedne pred kirurškim posegom.
You will also take iron supplements before and during Epoetin alfa HEXAL treatment to increase the effectiveness of Epoetin alfa HEXAL.
Med zdravljenjem z zdravilom Epoetin alfa HEXAL in po njem boste jemali tudi nadomestno železo za povečanje učinka zdravila Epoetin alfa HEXAL.
Adult patients scheduled for orthopaedic surgery
Odrasli bolniki, naročeni na večji ortopedski kirurški poseg
It is important that levels of iron in your blood are normal throughout Epoetin alfa HEXAL treatment.
Pomembno je, da so med zdravljenjem z zdravilom Epoetin alfa HEXAL vrednosti železa v vaši krvi normalne.
Where appropriate you will receive oral doses of iron, ideally starting before the Epoetin alfa HEXAL treatment begins.
Če je potrebno, boste prejeli peroralne odmerke železa, ki jih je treba začeti jemati pred zdravljenjem z zdravilom Epoetin alfa HEXAL.
If you are a kidney patient Epoetin alfa HEXAL has to be given by injection into a vein.
Če ste ledvični bolnik, je treba zdravilo Epoetin alfa HEXAL injicirati v veno.
At the start of your therapy, Epoetin alfa HEXAL may be injected by medical staff.
Na začetku zdravljenja vam bo zdravilo Epoetin alfa HEXAL injiciralo medicinsko osebje.
However, your doctor may decide that it is right for you to learn how to inject Epoetin alfa HEXAL under the skin yourself.
Toda zdravnik se lahko odloči, da je za vas primerno, da se zdravilo Epoetin alfa HEXAL naučite pod kožo injicirati sami.
Inject the Epoetin alfa HEXAL solution.
Injicirajte raztopino zdravila Epoetin alfa HEXAL.
If you inject more Epoetin alfa HEXAL than you should
Če ste uporabili večji odmerek zdravila Epoetin alfa HEXAL, kot bi smeli
You should inform the doctor immediately if you think too much Epoetin alfa HEXAL has been injected.
Če mislite, da ste uporabili prevelik odmerek zdravila Epoetin alfa HEXAL, o tem takoj obvestite svojega zdravnika.
Like all medicines, Epoetin alfa HEXAL can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Epoetin alfa HEXAL neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
203 If you experience headaches, particularly sudden, stabbing migraine-like headaches or feel confused or have fits, tell your doctor immediately.
Če se pojavijo glavoboli, še posebej nenadni, migreni podobni glavoboli z zbadanjem, ste zmedeni ali imate napade, o tem takoj obvestite svojega zdravnika.
formation of a blood clot may occur.
- Zvečano število trombocitov, kar lahko povzroči nastanek krvnega strdka.
Your doctor will check on this.
To bo preveril
PRCA means the inability to produce enough red blood cells in the bone (see section “ Take special care with Epoetin alfa HEXAL”).
Aplazija rdečih krvnih celic pomeni nezmožnost nastajanja zadostnega števila rdečih krvnih celic v kosteh (glejte poglavje » Bodite posebno pozorni pri uporabi zdravila Epoetin alfa HEXAL «).
Your doctor may monitor your blood pressure regularly while you are using Epoetin alfa HEXAL, particularly at the start of therapy.
Zdravnik lahko med zdravljenjem z zdravilom Epoetin alfa HEXAL redno spremlja vaš krvni tlak, še posebej na začetku zdravljenja.
- blood clotting (thrombotic vascular events) (see section “ Take special care with Epoetin alfa
- Krvni strdki (trombotični žilni dogodki) (glejte poglavje » Bodite posebno pozorni pri uporabi
HEXAL ”).
zdravila Epoetin alfa HEXAL «).
Therefore your haemoglobin-levels and your blood pressure should
Zato je treba nadzorovati koncentracijo hemoglobina in krvni tlak.
with underlying cardiovascular disease: after donating blood repeatedly vascular and thrombotic events (blood clotting) can occur independently of treatment with Epoetin alfa HEXAL.
z obstoječo boleznijo srca in ožilja: ne glede na zdravljenje z zdravilom Epoetin alfa HEXAL se lahko po darovanju krvi večkrat pojavijo žilni in trombotični dogodki (strjevanje krvi).
Treatment with Epoetin alfa HEXAL may be associated with an increased risk of blood clotting after the surgery (postoperative thrombotic/ vascular disorders) if your levels of the red blood pigment are too high.
Če so vrednosti rdečega pigmenta v krvi prevelike, je zdravljenje z zdravilom Epoetin alfa HEXAL lahko povezano z zvečanim tveganjem za pojav krvnih strdkov po operativnem posegu (pooperativne trombotične žilne motnje).
204 5.
204 Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
HOW TO STORE EPOETIN ALFA HEXAL
SHRANJEVANJE ZDRAVILA EPOETIN ALFA HEXAL
- Do not use this medicine after the expiry date which is stated on the label and carton after
- Zdravila Epoetin alfa HEXAL ne smete uporabljati po datumu izteka roka uporabnosti, ki je
“ EXP”.
naveden na nalepki in škatli poleg oznake » Uporabno do «.
- You may take Epoetin alfa HEXAL out of the refrigerator and keep it at room temperature (up
- Zdravilo Epoetin alfa HEXAL lahko vzamete iz hladilnika in ga hranite pri sobni temperaturi
to 25°C) for no longer than 3 days.
(ne višji od 25 °C), a ne dlje kot 3 dni.
What Epoetin alfa HEXAL contains
Kaj vsebuje zdravilo Epoetin alfa HEXAL
Epoetin alfa HEXAL 1000 IU/ 0.5 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.5 ml solution for injection contains 1000 international units (IU) corresponding to 8.4 micrograms epoetin alfa Epoetin alfa HEXAL 2000 IU/ 1 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 1 ml solution for injection contains 2000 international units (IU) corresponding to 16.8 micrograms epoetin alfa Epoetin alfa HEXAL 3000 IU/ 0.3 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.3 ml solution for injection contains 3000 international units (IU) corresponding to 25.2 micrograms epoetin alfa Epoetin alfa HEXAL 4000 IU/ 0.4 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.4 ml solution for injection contains 4000 international units (IU) corresponding to 33.6 micrograms epoetin alfa Epoetin alfa HEXAL 5000 IU/ 0.5 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.5 ml solution for injection contains 5000 international units (IU) corresponding to 42.0 micrograms epoetin alfa Epoetin alfa HEXAL 6000 IU/ 0.6 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.6 ml solution for injection contains 6000 international units (IU) corresponding to 50.4 micrograms epoetin alfa Epoetin alfa HEXAL 7000 IU/ 0.7 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.7 ml solution for injection contains 7000 international units (IU) corresponding to 58.8 micrograms epoetin alfa Epoetin alfa HEXAL 8000 IU/ 0.8 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.8 ml solution for injection contains 8000 international units (IU) corresponding to 67.2 micrograms epoetin alfa Epoetin alfa HEXAL 9000 IU/ 0.9 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 0.9 ml solution for injection contains 9000 international units (IU) corresponding to 75.6 micrograms epoetin alfa Epoetin alfa HEXAL 10 000 IU/ 1 ml solution for injection in a pre-filled syringe: one pre-filled syringe of 1 ml solution for injection contains 10 000 international units (IU) corresponding to 84.0 micrograms epoetin alfa
Epoetin alfa HEXAL 9. 000 i. e. / 0, 9 ml raztopina za injiciranje v napolnjeni injekcijski brizgi:
205
Epoetin alfa HEXAL 10. 000 i. e. / 1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi: ena napolnjena injekcijska brizga z 1 ml raztopine za injiciranje vsebuje 10. 000 mednarodnih enot (i. e.), kar ustreza 84, 0 mikrograma epoetina alfa.
Epoetin alfa HEXAL 1000 IU/ 0.5 ml solution for injection in a pre-filled syringe The syringes contain 0.5 ml (1000 IU) of solution.
Brizga vsebuje 0, 5 ml (1. 000 i. e.) raztopine.
Epoetin alfa HEXAL 2000 IU/ 1 ml solution for injection in a pre-filled syringe The syringes contain 1 ml (2000 IU) of solution.
Brizga vsebuje 1 ml (2. 000 i. e.) raztopine.
Epoetin alfa HEXAL 3000 IU/ 0.3 ml solution for injection in a pre-filled syringe The syringes contain 0.3 ml (3000 IU) of solution.
Brizga vsebuje 0, 3 ml (3. 000 i. e.) raztopine.
Epoetin alfa HEXAL 4000 IU/ 0.4 ml solution for injection in a pre-filled syringe The syringes contain 0.4 ml (4000 IU) of solution.
Brizga vsebuje 0, 4 ml (4. 000 i. e.) raztopine.
Epoetin alfa HEXAL 5000 IU/ 0.5 ml solution for injection in a pre-filled syringe The syringes contain 0.5 ml (5000 IU) of solution.
Brizga vsebuje 0, 5 ml (5. 000 i. e.) raztopine.
Epoetin alfa HEXAL 6000 IU/ 0.6 ml solution for injection in a pre-filled syringe The syringes contain 0.6 ml (6000 IU) of solution.
Brizga vsebuje 0, 6 ml (6. 000 i. e.) raztopine.
Epoetin alfa HEXAL 7000 IU/ 0.7 ml solution for injection in a pre-filled syringe The syringes contain 0.7 ml (7000 IU) of solution.
Brizga vsebuje 0, 7 ml (7. 000 i. e.) raztopine.
Epoetin alfa HEXAL 8000 IU/ 0.8 ml solution for injection in a pre-filled syringe The syringes contain 0.8 ml (8000 IU) of solution.
Brizga vsebuje 0, 8 ml (8. 000 i. e.) raztopine.
Epoetin alfa HEXAL 9000 IU/ 0.9 ml solution for injection in a pre-filled syringe The syringes contain 0.9 ml (9000 IU) of solution.
Brizga vsebuje 0, 9 ml (9. 000 i. e.) raztopine.
Epoetin alfa HEXAL 10 000 IU/ 1 ml solution for injection in a pre-filled syringe The syringes contain 1 ml (10 000 IU) of solution.
Brizga vsebuje 1 ml (10. 000 i. e.) raztopine.
Hexal AG Industriestrasse 25 D-83607 Holzkirchen Tel: + 49 8024 908-0 Fax: + 49 8024 908-1290 e-mail: service@hexal. com
206 Hexal AG Industriestrasse 25 D- 83607 Holzkirchen Tel: + 49 8024 908- 0 Faks: + 49 8024 908- 1290 e- naslov: service@ hexal. com
206 This leaflet was last approved in {MM/ YYYY}.
Navodilo je bilo odobreno {MM/ LLLL}.
This document is a summary of the European Public Assessment Report (EPAR).
Povzetek EPAR za javnost Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR).
Erbitux is used to treat the following types of cancer: • metastatic cancer of the colon or rectum (lower intestine or large bowel). ‘ Metastatic ’ means that the cancer has spread to other parts of the body.
Beseda „ metastatski “ pomeni, da se je rak že razširil na druge dele telesa.
Erbitux is used in patients whose tumour cells have a protein on their surface called epidermal growth factor receptor (EGFR) and contain a ‘ wild-type’ (non-mutated) gene called ‘ KRAS’.
Zdravilo Erbitux se uporablja pri bolnikih, katerih tumorske celice imajo na svoji površini beljakovino, imenovano receptor za epidermalni rastni faktor (RERF), in vsebujejo „ divji “ (nemutirani) tip gena, imenovanega „ KRAS “.
This gene stimulates tumour growth when it is mutated in tumour cells.
Ta gen v primeru svoje mutacije začne v tumorskih celicah spodbujati rast tumorja.
Erbitux is used together with other anticancer medicines, or on its own when previous cancer treatment containing oxaliplatin and irinotecan has failed and the patient cannot receive irinotecan; • ‘ squamous cell’ cancers of the head and neck.
Zdravilo Erbitux se uporablja skupaj z drugimi zdravili proti raku ali pa samostojno, kadar predhodno zdravljenje raka z zdravili, ki vsebujejo oksaliplatin in irinotekan, ni bilo uspešno in bolnik ne more več prejemati irinotekana; • ploščatoceličnega raka glave in vratu.
In locally advanced cancer (when the tumour has grown but has not spread), Erbitux is given in combination with radiotherapy (radiation therapy).
Pri lokalno napredovalnem raku (ko je tumor zrastel, vendar se ni razširil) se zdravilo Erbitux uporablja v kombinaciji z obsevanjem (radioterapijo).
In cancer that is recurrent (when it has come back after previous treatment) or metastatic, Erbitux is used with a ‘ platinum-based’ anticancer medicine combination (including medicines such as cisplatin or carboplatin).
Pri ponavljajočem (ki se ponovi po predhodnem zdravljenju) ali metastatskem raku se zdravilo Erbitux uporablja v kombinaciji z zdravili za zdravljenje raka na osnovi platine (vključno z zdravili, kot je cisplatin ali karboplatin).
Erbitux should only be given by doctors who have experience in the use of anticancer medicines.
Zdravilo Erbitux lahko predpiše le zdravnik, ki ima izkušnje z uporabo zdravil proti raku.
Before receiving Erbitux for the first time, the patient must be given an antihistamine and a corticosteroid to prevent an allergic reaction.
Pred prvo uporabo zdravila Erbitux je treba bolniku za preprečitev alergičnih reakcij dati antihistaminike in kortikosteroide.
This is also recommended for all subsequent infusions.
To je priporočljivo tudi pri vseh naslednjih infundiranjih.
Erbitux is given once a week.
Zdravilo Erbitux se daje enkrat tedensko.
The first infusion is given at a dose of 400 mg per square metre body surface area (calculated using the patient’ s height and weight) over two hours.
Odmerek pri prvem infundiranju znaša 400 mg na kvadratni meter telesne površine (izračunane na podlagi bolnikove mase in višine), ki ga bolniku infundiramo v trajanju dveh ur.
The following infusions are 250 mg/ m2 given over one hour.
Vsak naslednji odmerek je 250 mg/ m2 in se infundira eno uro.
When it is used on its own or with other anticancer medicines, Erbitux is continued for as long as the patient responds.
Kadar se zdravilo uporablja samostojno ali skupaj z drugimi zdravili proti raku, se zdravilo Erbitux bolniku daje tako tako dolgo, dokler se nanj odziva.
When it is used with radiotherapy, Erbitux is started one week before the radiotherapy starts and continued until the radiotherapy has finished.
Kadar se uporablja skupaj z obsevanjem, se zdravilo Erbitux začne dajati en teden pred začetkom obsevanja in se ga daje vse do konca obsevanja.
Erbitux has not been studied in patients with kidney, liver or blood problems, or in children.
Zdravilo Erbitux ni bilo preskušeno pri bolnikih z ledvičnimi in jetrnimi težavami ali težavami s krvjo oziroma pri otrocih.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found on certain cells in the body.
Monoklonsko protitelo je protitelo (vrsta beljakovine), ki je bilo zasnovano tako, da prepozna in se veže na določeno strukturo (imenovano antigen) na površini nekaterih celic v telesu.
Cetuximab has been designed to bind to EGFR, which can be found on the surface of certain tumour cells.
Zdravilna učinkovina cetuksimab je bila zasnovana tako, da se veže na receptor za epidermalni rastni faktor, ki ga najdemo na površini določenih tumorskih celic.
As a result of this binding, the tumour cell can no longer receive the messages needed for growth, progression and spread.
Posledica te vezave je, da tumorske celice ne morejo več prejemati sporočil, potrebnih za svojo rast, napredovanje in širjenje.
Between 79 and 89% of colorectal cancers and more than 90% of squamous cell cancers of the head and neck have EGFR on the cell surface.
Pri 79 do 89% primerov raka debelega črevesa ali danke in več kot 90% ploščatoceličnega raka glave in vratu je na površini tumorskih celic prisoten receptor za epidermalni rastni faktor.
For metastatic cancer of the colon or rectum, Erbitux was studied in five main studies: • two studies involved 1,535 patients who had not received chemotherapy before, looking at the effects of adding Erbitux to a treatment combination containing either irinotecan or oxaliplatin; • three studies involved 2,199 patients whose disease had got worse while they were on previous treatment including irinotecan, oxaliplatin or both, or who could not receive these medicines.
Pri metastatskem raku debelega črevesa ali danke so zdravilo Erbitux proučevali v petih glavnih študijah: • dve od teh študij, ki sta vključevali 1 535 bolnikov, ki predhodno še niso bili zdravljeni s kemoterapijo, sta preučevali učinkovitost dodajanja zdravila Erbitux kemoterapevtskemu zdravljenju s kombinacijo zdravil, ki so vsebovala irinotekan ali oksaliplatin; • druge tri študije so vključevale 2 199 bolnikov, pri katerih se je bolezen poslabšala med predhodno kemoterapijo, ki je vključevala irinotekan ali oksaliplatin ali pa obe učinkovini, ali pri katerih teh zdravil ni bilo mogoče uporabiti.
For cancers of the head and neck, Erbitux was investigated in two main studies: • the first study involved 424 patients with locally advanced cancer, looking at the effects of adding Erbitux to radiotherapy; • the second study involved 442 patients with recurrent or metastatic cancer, looking at the effects of adding Erbitux to a platinum-based anticancer medicine combination.
Pri raku glave in vratu so zdravilo Erbitux proučevali v dveh glavnih študijah: • pri 424 bolnikov z lokalno napredovalnim rakom, vključenih v prvo študijo, so proučevali učinke dodajanja zdravila Erbitux med obsevanjem; • pri 442 bolnikov s ponavljajočim ali metastatskim rakom, vključenih v drugo študijo, so proučevali učinke dodajanja zdravila Erbitux kombinaciji zdravil proti raku na osnovi platine.
All of the studies looked at the length of time before the patient’ s cancer started to get worse or how long the patients survived.
V vseh študijah so opazovali čas napredovanje bolnikovega raka ali čas preživetja bolnikov.
In the studies of cancer of the colon or rectum, it took longer until the disease got worse in the patients with wild-type KRAS in their tumours when they received Erbitux: • in patients who had not received chemotherapy before, it took longer for the disease to get worse when they received Erbitux in addition to chemotherapy than when they did not add Erbitux.
V študijah raka debelega črevesa in danke je bil čas do poslabšanja bolezni pri bolnikih z divjim tipom gena KRAS v tumorju, ki so prejemali zdravilo Erbitux, daljši: • pri bolnikih, ki predhodno niso bili zdravljeni s kemoterapijo, je pri tistih, ki so prejemali zdravilo Erbitux kot dodatek k kemoterapiji, trajalo dlje časa, da se je bolezen poslabšala, kot pri tistih, ki niso prejemali zdravila Erbitux.
This included chemotherapy including irinotecan (9.9 months compared with 8.7 months, on average) and including oxaliplatin (7.7 months compared with 7.2 months, on average) in patients who did not receive Erbitux. • the first study in patients who had taken chemotherapy before did not look at KRAS mutations.
To je vključevalo kemoterapijo, ki je vključevala irinotecan (povprečno 9, 9 meseca v primerjavi z 8, 7 meseca) in oksaliplatin (povprečno 7, 7 meseca v primerjavi s 7, 2 meseca) pri bolnikih, ki niso prejemali zdravila Erbitux. • v prvi študiji, izvedeni pri bolnikih, ki so predhodno že prejemali kemoterapijo, niso opazovali mutacije gena KRAS.
In the other two studies, it took longer for the disease to get worse among patients with wild-type KRAS when Erbitux was added to their treatment.
V drugih dveh študijah je v skupini bolnikov z divjim tipom gena KRAS do poslabšanja bolezni prišlo pozneje kot pri bolnikih, pri katerih se je zdravilo Erbitux dodajalo k zdravljenju.
In patients who had failed both oxaliplatin and irinotecan treatment, it took an average of 3.6 months with Erbitux and 1.9 months in those receiving best supportive care alone (the treatment of symptoms but not the cancer itself).
V skupini bolnikov, pri katerih zdravljenje z oksaliplatinom in irinotecanom ni bilo uspešno, je do poslabšanja prišlo po povprečno 3, 6 meseca pri bolnikih, ki so prejemali zdravilo Erbitux, in 2, 6 meseca pri bolnikih, ki so prejemali samo podporno nego (zdravljenje simptomov, a ne samega raka).
In patients who had failed oxaliplatin treatment, it took an average of 4.0 months with Erbitux plus irinotecan and 2.6 months in those receiving irinotecan alone.
V skupini bolnikov, pri katerih zdravljenje z oksaliplatinom ni bilo uspešno, je do poslabšanja prišlo po povprečno 4, 0 meseca pri bolnikih, ki so prejemali zdravilo Erbitux in irinotekan, in 2, 6 meseca pri bolnikih, ki so prejemali samo irinotekan.
In locally advanced head and neck cancers, it took longer for the disease to get worse when Erbitux was added to radiotherapy (24.4 months compared with 14.9 months).
Pri lokalno napredovalnem raku glave in vratu je bil čas do poslabšanja bolezni daljši pri bolnikih, ki so prejemali zdravilo Erbitux kot dodatek k obsevanju (24, 4 meseca v primerjavi s 14, 9 meseca).
In recurrent or metastatic head and neck cancer, survival was longer when Erbitux was added to a platinum-based anticancer medicine combination (10.1 months compared with 7.4 months).
Pri ponavljajočem ali metastatskem raku glave in vratu je bil čas preživetja daljši, kadar se je zdravilo Erbitux dodajalo kombinaciji zdravil proti raku na osnovi platine (10, 1 meseca v primerjavi s 7, 4 meseca).